PCV15

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

3 competitors in Pneumococcal Vaccines

#DrugCompanyPhaseTrials

1

Seasonal Influenza Vaccine

Novartis

Phase 3

12

31-Valent Pneumococcal Conjugate Vaccine

VVaxcyte, Inc.

Phase 3

23

PCV15

Merck & Co.

Phase 3

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity2 trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Completed·Merck & Co.·Phase 3·NCT05420961·717 enrolled

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Completed·Pfizer·Phase 1·NCT05489328·394 enrolled

Pneumococcal Disease2 trials

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Completed·Merck & Co.·Phase 3·NCT05696080·518 enrolled

A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants

Active, not recruiting·Pfizer·Phase 2·NCT06524414·605 enrolled

Immunodeficiency1 trial

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Completed·Merck & Co.·Phase 3·NCT05393037·313 enrolled

Vaccination1 trial

MISP 60528 Pneumococcal Vaccination

Terminated·MMontefiore Medical Center··NCT04845945·4 enrolled

Pneumococcal Vaccines1 trial

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

Recruiting·UUniversity of Oxford·Phase 4·NCT06731374·106 enrolled

Details

Drug Info

Related News